Omeros Corporation (OMER) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Omeros Corporation stock (OMER) is currently trading at $10.44. Omeros Corporation PS ratio (Price-to-Sales) is 4.93. Analyst consensus price target for OMER is $38.00. WallStSmart rates OMER as Sell.
- OMER PE ratio analysis and historical PE chart
- OMER PS ratio (Price-to-Sales) history and trend
- OMER intrinsic value — DCF, Graham Number, EPV models
- OMER stock price prediction 2025 2026 2027 2028 2029 2030
- OMER fair value vs current price
- OMER insider transactions and insider buying
- Is OMER undervalued or overvalued?
- Omeros Corporation financial analysis — revenue, earnings, cash flow
- OMER Piotroski F-Score and Altman Z-Score
- OMER analyst price target and Smart Rating
Omeros Corporation
📊 No data available
Try selecting a different time range
Smart Analysis
Omeros Corporation (OMER) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Omeros Corporation (OMER) Key Strengths (0)
Supporting Valuation Data
Omeros Corporation (OMER) Areas to Watch (7)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Very expensive at 8.4x book value
Premium valuation at 4.9x annual revenue
Small-cap company with higher risk but more growth potential
Solid revenue growth at 14.90% per year
Moderate institutional interest at 47.39%
Supporting Valuation Data
Omeros Corporation (OMER) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 3.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Price/Book. Some valuation metrics including PEG Ratio (N/A), Price/Sales (4.93), Price/Book (8.44) suggest expensive pricing. Growth concerns include Revenue Growth at 14.90%, which may limit upside. Profitability pressure is visible in Return on Equity at -576.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -576.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 14.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
OMER Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
OMER's Price-to-Sales ratio of 4.93x trades at a deep discount to its historical average of 226.34x (19th percentile). The current valuation is 100% below its historical high of 3199.05x set in Apr 2015, and 480% above its historical low of 0.85x in Oct 2023. Over the past 12 months, the PS ratio has compressed from ~6.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Omeros Corporation (OMER) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Omeros Corporation operates as a stable business with moderate growth and solid fundamentals. Revenue reached -30M with 15% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -18M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.52, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Omeros Corporation.
Bottom Line
Omeros Corporation offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(7 last 3 months)
| Insider | Type | Shares |
|---|---|---|
BORGES, DAVID J. VP, Finance & CAO | Sell | -30,000 |
Data sourced from SEC Form 4 filings
Last updated: 8:26:18 AM
About Omeros Corporation(OMER)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.